Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Nektar Therapeutics    NKTR

NEKTAR THERAPEUTICS

(NKTR)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/21/2020 10/22/2020 10/23/2020 10/26/2020 10/27/2020 Date
16.615(c) 17.18(c) 17.54(c) 16.97(c) 16.47 Last
1 192 294 940 971 677 515 947 315 941 224 Volume
-3.23% +3.40% +2.10% -3.25% -2.95% Change
More quotes
Financials (USD)
Sales 2020 147 M - -
Net income 2020 -503 M - -
Net cash position 2020 170 M - -
P/E ratio 2020 -6,00x
Yield 2020 -
Sales 2021 171 M - -
Net income 2021 -473 M - -
Net cash position 2021 46,3 M - -
P/E ratio 2021 -6,52x
Yield 2021 -
Capitalization 3 036 M 3 036 M -
EV / Sales 2020 19,4x
EV / Sales 2021 17,5x
Nbr of Employees 723
Free-Float 99,2%
More Financials
Company
Nektar Therapeutics specializes in the research and development of drugs for the treatment of cancer, autoimmune diseases and chronic pain. Net sales break down by source of income as follows: - revenues from licensing and collaboration agreements (91.9%); - product sales (4.6%); - royalties (3.5%). At the end of 2018, the Group had a portfolio of 11 products in clinical development (including 4 in phase III, 3... 
More about the company
Notations Surperformance© of Nektar Therapeutics
Trading Rating : Investor Rating :
More Ratings
All news about NEKTAR THERAPEUTICS
10/02NEKTAR THERAPEUTICS : Change in Directors or Principal Officers (form 8-K)
AQ
08/12NEKTAR THERAPEUTICS : Vaccibody AS and Nektar Therapeutics Announce First Patien..
PR
08/07NEKTAR THERAPEUTICS : Management's Discussion and Analysis of Financial Conditio..
AQ
08/06NEKTAR : 2Q Earnings Snapshot
AQ
08/06NEKTAR THERAPEUTICS : Results of Operations and Financial Condition, Financial S..
AQ
07/28NEKTAR THERAPEUTICS : to Announce Financial Results for the Second Quarter 2020 ..
PR
06/23NEKTAR THERAPEUTICS : Submission of Matters to a Vote of Security Holders, Other..
AQ
06/04NEKTAR THERAPEUTICS : Data Presented from Phase 1b Study of NKTR-358, a Novel T ..
PR
05/29NEKTAR THERAPEUTICS : to Host Webcast Conference Call for Analysts & Investors D..
PR
05/08NEKTAR THERAPEUTICS : Management's Discussion and Analysis of Financial Conditio..
AQ
05/07NEKTAR : 1Q Earnings Snapshot
AQ
05/07NEKTAR THERAPEUTICS : Results of Operations and Financial Condition, Financial S..
AQ
05/07NEKTAR THERAPEUTICS : Reports First Quarter 2020 Financial Results
PR
04/28NEKTAR THERAPEUTICS : to Announce Financial Results for the First Quarter 2020 o..
PR
04/02NEKTAR THERAPEUTICS : Regulation FD Disclosure, Financial Statements and Exhibit..
AQ
More news
News in other languages on NEKTAR THERAPEUTICS
2019EN DIRECT DES MARCHES : ArcelorMittal, Airbus, Carrefour, Altran, Inventiva, ..
2019STOCK MARKET PARIS : Donald Trump à quitte ou double
2019WallStreet : Donald Trump plombe le S&P, les taux, le pétrole
More news
Chart NEKTAR THERAPEUTICS
Duration : Period :
Nektar Therapeutics Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEKTAR THERAPEUTICS
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 30,83 $
Last Close Price 16,97 $
Spread / Highest target 371%
Spread / Average Target 81,7%
Spread / Lowest Target 0,18%
EPS Revisions
Managers
NameTitle
Howard W. Robin President, Chief Executive Officer & Director
Robert B. Chess Chairman
Gilbert M. Labrucherie Senior VP, Chief Operating & Financial Officer
Jonathan Zalevsky Chief Research & Development Officer
Roy A. Whitfield Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
NEKTAR THERAPEUTICS-21.38%3 036
LONZA GROUP AG62.63%47 039
SEAGEN INC.71.39%34 074
IQVIA HOLDINGS INC.4.96%31 092
CELLTRION, INC.32.04%28 087
MODERNA, INC.259.10%27 716